PR5I

BIOLOGICAL2 trials

Sponsors

MCM Vaccines B.V.

Conditions

Bacterial InfectionsNeisseria MeningitidisVirus Diseases

Phase 3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

CompletedNCT01480258

MCM Vaccines B.V.Bacterial Infections, Virus Diseases

Start: 2011-11-23End: 2013-10-09Updated: 2019-04-02

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

CompletedNCT01839188

MCM Vaccines B.V.Bacterial Infections, Neisseria Meningitidis, Virus Diseases

Start: 2013-05-01End: 2014-03-19Updated: 2019-02-25

Related Papers

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).

2017-06-0213 citations

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

2016-06-1828 citations